Fig 1.

Trial profile. A total of 111 patients with disease classified as localized high-risk disease assessed for eligibility did not meet eligibility criteria: insufficient diagnosis criteria or diagnosis rejected (n = 14); persisting toxicity related to previous treatment and/or contraindication to planned treatment (n = 78), including contraindication to busulfan and melphalan (BuMel) because of planned radiotherapy to an axial site (n = 36); early radiotherapy (n = 13); psychological problems (n = 6); 123 patients meeting eligibility criteria were not enrolled because of other reasons. HDT, high dose therapy; R2Loc, selected high-risk population; VAI, vincristine, dactinomycin, and ifosfamide.